Liquid–liquid phase separation (LLPS) is rapidly gaining recognition as a foundational mechanism in cell biology, biophysics, and therapeutic innovation. Once considered cellular noise, LLPS is now known to organize biomolecules into dynamic, membrane-less compartments known as biomolecular condensates. These liquid-like structures play critical roles in gene regulation, RNA metabolism, and signal transduction, offering a powerful new lens through which to understand health and disease.

Lipid nanoparticles (LNPs) have played a central role in the rise of RNA-based therapeutics and vaccines, including the rapid development of mRNA COVID-19 vaccines. But while LNPs have proven their utility in certain contexts, their limitations are becoming increasingly clear. As biologic therapies become more complex and personalized, we need delivery technologies that go further—safer, simpler, and more flexible.

As next-generation biologics reshape the future of medicine, the way we deliver these molecules into cells has never been more critical. For decades, viral vectors have dominated intracellular delivery, particularly in gene therapy and cell-based treatments. But concerns around safety, cost, scalability, and immune response are prompting a significant shift: toward non-viral delivery systems.